Update of intravitreal steroids for the treatment of diabetic macular edema

Ophthalmic Research

Volumn 52, Issue 2, 2014, Pages 89-96

  Bandello, Francesco ^a   Preziosa, Chiara ^a   Querques, Giuseppe ^a   Lattanzio, Rosangela ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Dexamethasone implant; Diabetic macular edema; Fluocinolone acetonide; Intravitreal pharmacotherapies; Steroids; Triamcinolone acetonide

Indexed keywords

DEXAMETHASONE; FLUOCINOLONE ACETONIDE; TRIAMCINOLONE ACETONIDE; GLUCOCORTICOID;

CATARACT EXTRACTION; CENTRAL RETINAL THICKNESS; DIABETIC MACULAR EDEMA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SOLUBILITY; FOLLOW UP; HUMAN; LASER COAGULATION; LIPOPHILICITY; OPHTHALMIC DRUG DELIVERY DEVICE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUSTAINED DRUG RELEASE; DIABETIC RETINOPATHY; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA;

DIABETIC RETINOPATHY; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; TRIAMCINOLONE ACETONIDE;

EID: 84926295693     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000362764     Document Type: Review

References (57)

1. Aroca PR, Salvat M, Fernandez J, et al. Risk factors for diffuse and focal macular edema. J Diabetes Compl 2004; 18: 211-215
2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053
3. Chen E, Looman M, Laouri M, et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin 2010; 26: 1587-1597
4. Ferris FL III, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol 1984; 28(suppl):452-461
5. American Academy of Ophthalmology Retina Panel Preferred Practice Pattern Guidelines: Diabetic Retinopathy. San Francisco, American Academy of Ophthalmology, 2010
6. Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985; 103: 1796-1806
7. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625
8. Diabetic Retinopathy Clinical Research Network: Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064-1077
9. Diabetic Retinopathy Clinical Research Network: Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118: 609-614
10. Bhagat N, Grigorian RA, Tutela A, et al. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009; 54: 1-32
11. Funatsu H, Yamashita H, Noma H, et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 2002; 133: 70-77
12. Funatsu H, Yamashita H, Ikeda T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2003; 110: 1690-1696
13. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142: 961-969
14. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33: 2399-2405
15. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119: 789-801
16. Do DV, Nguyen QD, Khwaja AA, et al. Ranibizumab for Edema of the Macula in Diabetes Study: 3-year outcomes and the need for prolonged frequent treatment (READ-2). Arch Ophthalmol 2012; 8: 1-7
17. Elman MJ, Qin H, Aiello LP, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012; 119: 2312-2318
18. Scott IU, Edwards AR, Beck RW, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114: 1860-1867
19. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012; 130: 972-979
20. Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009; 116: 1142-1150
21. Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747-1757
22. Sultan MB, Zhou D, Loftus J, et al. A phase 2/3, multicenter, randomized, doublemasked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011; 118: 1107-1118
23. Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012; 119: 1658-1665
24. Summary of Product Characteristics 2011. Basel, Novartis Pharma, 2011
25. Nauck M, Roth M, Tamm M, et al. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is down-regulated by corticosteroids. Am J Respir Cell Mol Biol 1998; 16: 398-406
26. Tamura H, Miyamoto K, Kiryu J, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005; 46: 1440-1444
27. Penfold P, Gyory J, Hunyor A, et al. Exudative macular degeneration and intravitreal Triamcinolone. A pilot study. Aust NZ J Ophthalmol 1995; 23: 292-298
28. Jonas J, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001; 132: 425-427
29. Audren F, Erginay A, Haouchine B, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 2006; 84: 624-630
30. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004; 111: 218-224
31. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005; 140: 695-702
32. Jonas JB, Kampperter BA, Harder B, et al. Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 2006; 22: 200-207
33. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: threemonth efficacy and safety results of a prospective, randomized, double-masked, placebo controlled clinical trial. Ophthalmology 2004; 111: 2044-2049
34. Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006; 113: 1533-1538
35. Gillies MC, Simpson JM, Gaston C, et al. Fiveyear results of a randomized trial with openlabel extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology 2009; 116: 2182-2187
36. Diabetic Retinopathy Clinical Research Network: A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115: 1447-1449
37. Diabetic Retinopathy Clinical Research Network: Three-year follow-up of a randomized clinical trial comparing focal/grid laser photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127: 245-251
38. Bressler NM, Edwards AR, Beck RW, et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol 2009; 127: 1566-1571
39. Diabetic Retinopathy Clinical Research Network: Randomized trial evaluating shortterm effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema following focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina 2011; 31: 1009-1027
40. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for non-infectious posterior uveitis: thirty-fourweek results of a multicenter randomized clinical study. Ophthalmology 2006; 113: 1020-1027
41. Pearson PA, Comstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011; 118: 1580-1587
42. Campochiaro PA, Hafiz G, Shah SM, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010; 117: 1393-1399
43. Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011; 118: 626-635
44. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012; 119: 2125-2132
45. Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129: 545-553
46. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134-1146
47. Haller JA, Dugel P, Weinberg DV, et al. Evaluation of safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 2009; 29: 46-51
48. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125: 309-317
49. Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010; 128: 289-296
50. Boyer DS, Faber D, Gupta S, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011; 31: 915-923
51. Zucchiatti I, Lattanzio R, Querques G, et al. Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthalmologica 2012; 228: 117-122
52. Pacella E, Vestri AR, Muscella R, et al. Preliminary results of an intravitreal dexamethasone implant (Ozurdex ® ) in patients with persistent diabetic macular edema. Clin Ophthalmol 2013; 7: 1423-1428
53. Lazic R, Lukic M, Boras I, et al. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina 2014; 34: 719-724
54. Callanan D, Gupta S, Boyer D, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013; 120: 1843-1851
55. Bandello F, Battaglia Parodi M, Tremolada G, et al. Steroids as part of combination treatment: the future for the management of macular edema?. Ophthalmologica 2010; 224(suppl 1):41-45
56. Bandello F, Zarbin MA, Lattanzio R, Zucchiatti I. Clinical Strategies in the Management of Diabetic Retinopathy: A Step-by-Step Guide for Ophthalmologists. Berlin, Springer, 2013
57. Stewart MW. Corticosteroid use for diabetic macular edema: old fad or new trend?. Curr Diab Rep 2012; 12: 364-375